Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical Inc., a leader in photodisinfection therapies, is gearing up for a fundraising event through a placement and subscription to support its operating capital, U.S. clinical trials, and the sales growth of its Steriwave® nasal therapy. Prior to this fundraising, CEO Carolyn Cross and her husband, a significant shareholder, provided interim funding to the company with expectations of share issuance and repayment agreements. These transactions are considered related party transactions, with detailed disclosures to follow as per regulatory requirements.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.
